Research Overview
CXXC5 as a brake on Wnt signalling
Wnt/β-catenin signalling is regulated at several points, and CXXC5 contributes by binding Dishevelled and dampening downstream β-catenin stabilisation. Interest in this node came from observations that CXXC5 expression rises in contexts where regeneration is impaired, which made the CXXC5–Dishevelled interface an attractive target for a decoy peptide rather than for a small-molecule inhibitor.
Design of the fusion peptide
PTD-DBM addresses two problems at once. The Dishevelled-binding motif supplies the competing sequence, while the protein transduction domain provides membrane translocation so the motif can reach an intracellular partner. This architecture is common in tool-compound design, and the same caveats apply: transduction efficiency, intracellular stability and off-target binding all need to be verified in the specific system under study.
Hair-follicle and skin models
Experimental controls to consider
Because the construct combines two functional elements, informative designs usually include the transduction domain alone, a scrambled DBM sequence and a pathway readout such as TOPFlash reporter activity or β-catenin immunoblotting. Vehicle composition matters as well, since topical delivery in the original studies used specific solvent systems.
Material and analysis
The peptide is produced by solid-phase synthesis and purified by reverse-phase chromatography. Highly basic transduction domains can affect chromatographic behaviour and solubility, so net peptide content and counter-ion information on the certificate of analysis are worth reading before normalising concentrations across lots.
